Our research program focuses on the mechanisms of pathogenesis of important hospital-acquired pathogens. More specifically, Acinetobacter baumannii, an emerging gram-negative bacterium, Staphylococcus aureus, a gram-positive bacterium, and Candida albicans, the most common human fungal pathogen. We combine bacterial and fungal genetic techniques with exciting in vivo infection model systems (mammalian and non-mammalian [Caenorhabditis elegans and Zebrafish) to characterise the role of novel genes in virulence and antimicrobial resistance. Our over-arching goal is to identify new targets that may be amenable for future drug development, with a focus on microbial virulence, persistence and adaptation.